OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner




  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended for other attorneys. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-2017

« Janssen Wins Trial Verdict in Risperdal Case Against Mylan and Dr. Reddy's | Main | Mylan Wins Motion to Dismiss One of Two Patents-in-Suit in Norvasc Case Against Pfizer »

October 19, 2006



Third Party payors are ignoring the discontinuance of lower priced generic forms of Oxycontin, and refusing to reimburse above outdated MAC pricing. Anthem/Wellpoint is accepting prescription claims and expecting pharmacies to take a loss of up to $200 per prescription. After being contacted and informed of current market pricing, they are still maintaining their position.

The comments to this entry are closed.